Orexo

Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies

Retrieved on: 
Monday, January 9, 2023

), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals and vaccines in collaboration with leading international biopharmaceutical and vaccine companies.

Key Points: 
  • ), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals and vaccines in collaboration with leading international biopharmaceutical and vaccine companies.
  • The feasibility studies follow successful formulation of the Covid-19 spike protein in amorphOX®.
  • Orexo has expanded the application of the amorphOX® platform, from small molecules to also cover larger biomolecules.
  • Orexo's ambition is to work with leading companies to test the feasibility of the amorphOX® platform on their biomolecule or technology.

Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies

Retrieved on: 
Monday, January 9, 2023

), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals and vaccines in collaboration with leading international biopharmaceutical and vaccine companies.

Key Points: 
  • ), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals and vaccines in collaboration with leading international biopharmaceutical and vaccine companies.
  • The feasibility studies follow successful formulation of the Covid-19 spike protein in amorphOX®.
  • Orexo has expanded the application of the amorphOX® platform, from small molecules to also cover larger biomolecules.
  • Orexo's ambition is to work with leading companies to test the feasibility of the amorphOX® platform on their biomolecule or technology.

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

Retrieved on: 
Friday, January 6, 2023

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.

Key Points: 
  • James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.
  • He is currently Chairman at Orexo AB, Sutura Therapeutics and Celleron Therapeutics and non-executive director of Nasdaq listed company Lava Therapeutics N.V.
  • Douglas Thomson, CEO of Pneumagen, commented, "We are very pleased to welcome James to the Board who brings a wealth of strategic, corporate and financial expertise to Pneumagen.
  • James Noble added "I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data.

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

Retrieved on: 
Friday, January 6, 2023

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.

Key Points: 
  • James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.
  • He is currently Chairman at Orexo AB, Sutura Therapeutics and Celleron Therapeutics and non-executive director of Nasdaq listed company Lava Therapeutics N.V.
  • Douglas Thomson, CEO of Pneumagen, commented, "We are very pleased to welcome James to the Board who brings a wealth of strategic, corporate and financial expertise to Pneumagen.
  • James Noble added "I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data.

Orexo to Webcast Live at VirtualInvestorConferences.com December 15th  

Retrieved on: 
Wednesday, December 14, 2022

This will be a live, interactive online event where investors are invited to ask the company questions in real-time.

Key Points: 
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health.
  • Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US.

The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6%

Retrieved on: 
Monday, November 7, 2022

Key Points: 
  • NEW YORK, Nov. 7, 2022 /PRNewswire/ -- The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period.
  • The adoption of digital therapeutics is growing at a fast pace owing to factors such as rise in number of patients with chronic diseases and growing investments in digital therapeutics.
  • On the basis of application, the digital therapeutics market is divided into preventive and treatment/care-related applications.
  • On the basis of sales channel, the digital therapeutics market is divided into business-to-customer (B2C) and business-to-business (B2B).

Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Retrieved on: 
Friday, October 28, 2022

), (STO:ORX) (OTCQX:ORXOY), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA as part of a clinician supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD).

Key Points: 
  • ), (STO:ORX) (OTCQX:ORXOY), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA as part of a clinician supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD).
  • The randomized, open-label, parallel-group study is evaluating whether the use of MODIA in combination with sublingual buprenorphine/naloxone background therapy is superior to sublingual buprenorphine/naloxone alone to reduce illicit opioid use.
  • The study enrolled 437 participants at 35 sites across the US who voluntarily sought treatment for documented moderate to severe OUD.
  • "The medically assisted treatment of OUD requires a complete treatment plan that includes psychosocial support," said Nikolaj Srensen, President and CEO of Orexo.

Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Retrieved on: 
Friday, October 28, 2022

The randomized, open-label, parallel-group study is evaluating whether the use of MODIA in combination with sublingual buprenorphine/naloxone background therapy is superior to sublingual buprenorphine/naloxone alone to reduce illicit opioid use.

Key Points: 
  • The randomized, open-label, parallel-group study is evaluating whether the use of MODIA in combination with sublingual buprenorphine/naloxone background therapy is superior to sublingual buprenorphine/naloxone alone to reduce illicit opioid use.
  • The study enrolled 437 participants at 35 sites across the US who voluntarily sought treatment for documented moderate to severe OUD.
  • "The medically assisted treatment of OUD requires a complete treatment plan that includes psychosocial support," said Nikolaj Srensen, President and CEO of Orexo.
  • "However, access to quality counselling remains one of the main barriers to successful treatment in many areas of the US.